You did the infusions. Your friend felt great. You felt almost nothing.
If you have looked into NAD+ therapy for fatigue, you have probably run into the same thing twice: someone who says it changed their life, and someone who says it did nothing at all. Both of them are telling the truth. And in 2026, the research finally started explaining why.
Three reviews published this year converge on a point that is easy to miss in wellness marketing. Raising the level of a molecule in your bloodstream is not the same thing as changing how your cells behave. That gap is where most of the disagreement about NAD+ lives.
What NAD+ actually is, in plain English
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme your cells use constantly. It sits at the center of energy metabolism, redox balance, and the signaling pathways tied to aging and metabolic health. When researchers describe declining NAD+ with age, they are describing something real and well documented in cell and animal work.
That is why NAD+ became a longevity story. The mechanism is genuinely compelling. The question is what happens when you try to intervene.
What the research agrees on
The 2026 review in Molecular Biology Reports is clear on one point: oral NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) can increase circulating NAD+ levels. In research terms, that is target engagement. The supplement does the biochemical thing it claims to do.
That is not a small finding. Plenty of supplements never clear that bar.
What the research does not agree on
The same review states that clinical benefits “remain variable and context-dependent.” A separate review in Nature Metabolism put it more bluntly, concluding that despite promising preclinical data, human clinical trials have shown limited efficacy, and that the published body of data on NAD+ dynamics in human tissues remains sparse.
So the level goes up. Whether you feel different is a separate question, and the honest answer is that it depends.
The response is not a straight line
The Molecular Biology Reports authors modeled NAD+ responses mathematically and found they are nonlinear, shaped by dose, age, metabolic state, and route of administration. Rather than a simple more-in-means-more-out relationship, NAD+ supplementation appears to operate within a regulatory system involving feedback mechanisms and biological saturation.
In practical terms: past a certain point, your body pushes back. A bigger bag is not automatically a better result, and any clinic selling one as a premium upgrade is making a claim the current evidence does not support.
Blood is not tissue
The second gap matters more. Most human studies measure NAD+ in blood, because blood is what you can easily sample. What actually matters is NAD+ inside muscle, brain, and liver cells, and the human data on that is thin. A person whose blood level rises nicely may or may not be changing anything in the tissue that is making them tired.
Where the IV route sits in the evidence
This is the part we would rather not have to say, because we offer NAD+ IV therapy. The 2026 Molecular Biology Reports review states that intravenous NAD+ administration is less well characterized than oral precursors and lacks robust clinical validation.
That is not the same as saying it does not work. It means the controlled trials that would settle the question have largely not been done, and the oral route is currently the better-studied one. NAD+ IV therapy is not FDA-approved for treating fatigue, aging, or any of the conditions discussed here. Anyone who tells you the research is settled is not describing the research.
We think patients can handle that, and we would rather you hear it from us than discover it later.
Why fatigue is rarely one broken thing
There is a second reason results vary, and it has nothing to do with the molecule. It has to do with what is actually causing your fatigue.
A review published in Nutrients in August 2026, looking at ME/CFS and fibromyalgia, described mitochondrial dysfunction, oxidative and nitrosative stress, immune dysregulation, and altered redox and NAD+ metabolism as interconnected contributors to fatigue. Not a single switch. A web.
The same review examined NAD+ precursors alongside B vitamins, magnesium, CoQ10, alpha-lipoic acid, GlyNAC, L-carnitine, taurine, and creatine, and drew a distinction worth repeating: biochemical plausibility is not the same as established clinical efficacy. For several of these interventions, disease-specific randomized controlled evidence remains limited.
A 2026 review in Current Nutrition Reports, drawing on 32 human studies, reached a compatible conclusion. NAD+ precursors, antioxidants, glycine, and N-acetylcysteine show potential for mitochondrial efficiency and cellular stress responses, but findings vary across populations and dosing strategies, and that heterogeneity points toward individualized, context-specific application rather than one protocol for everyone.
That is the whole argument for working something up before infusing it.
What to ask before you book anywhere
- What are we treating? If nobody has looked for thyroid, iron, sleep apnea, anemia, or medication effects, an infusion is a guess.
- Why this route? There should be a reason for IV over oral in your specific case, not just a price list.
- What would tell us it worked? Agree on what you are measuring before the first session.
- What happens if it does not? A clinic with one answer for everyone has one answer for you.
Who is generally not a good candidate
We turn people away from this regularly, and it is worth being specific about who.
If your fatigue has an identified, treatable cause that has not been addressed yet, that comes first. Untreated sleep apnea, iron deficiency, thyroid disease, uncontrolled diabetes, depression, and certain medications all cause exactly the tiredness people bring to an infusion clinic, and none of them are corrected by NAD+.
People who are pregnant or breastfeeding, people in active cancer treatment without their oncology team involved, and people with significant kidney or liver impairment are generally not candidates without direct coordination with the physician managing that condition. If you are looking for a single session to resolve years of exhaustion, we are not the right fit, and we will tell you that on the phone rather than after you have paid.
Candidates are typically evaluated during a consultation, and part of that evaluation is deciding whether this is the wrong tool for your problem.
Frequently asked questions
Does NAD+ therapy actually work?
For raising circulating NAD+, yes. Oral precursors reliably do that. For improving fatigue, energy, or cognition, the 2026 evidence describes results as variable and context-dependent, with limited efficacy in human trials to date. It depends heavily on what is causing your symptoms.
Is IV NAD+ better than taking NMN or NR by mouth?
Not according to the current evidence. The 2026 Molecular Biology Reports review describes IV NAD+ as less well characterized and lacking robust clinical validation, while oral precursors have clearer evidence for raising NAD+ levels. IV may suit some situations, but it is not the better-studied option.
How long does it take to feel anything from NAD+ therapy?
There is no established timeline in the research, and reported experiences vary widely. Some patients report changes within days, others notice nothing. Results vary, and no outcome is guaranteed.
Is a higher NAD+ dose more effective?
The 2026 modelling work suggests not. NAD+ responses appear nonlinear, with feedback mechanisms and biological saturation, meaning higher doses do not straightforwardly produce larger effects.
Can NAD+ therapy help chronic fatigue syndrome or fibromyalgia?
The 2026 Nutrients review identifies altered NAD+ metabolism as one of several interconnected contributors to fatigue in these conditions, but notes that disease-specific randomized controlled evidence remains limited for several nutrient interventions. It is a reasonable thing to discuss with a provider, not a settled treatment.
Is NAD+ IV therapy FDA-approved?
No. NAD+ IV therapy is not FDA-approved for treating fatigue, aging, cognitive symptoms, or the conditions discussed in this article.
Why do some people respond and others do not?
The research points to several reasons at once: dose, age, metabolic state, route of administration, how much NAD+ actually reaches tissue rather than just blood, and whether NAD+ was the relevant problem in the first place.
Where can I get NAD+ therapy in Oklahoma City?
Venturis Clinic offers NAD+ IV therapy along with vitamin infusion therapy and ATP infusion for cellular health, as part of a workup rather than instead of one.
Talk to us before you spend money on this
Dr. Alvin Philipose has spent over 25 years in regenerative and functional medicine, and the most useful thing we do for fatigue patients is often the first conversation, not the first infusion. If NAD+ is not your problem, we would rather find that out together.
Venturis Clinic
7917 N May Ave, Suite B
Oklahoma City, OK 73120
(405) 848-7246
Book a free 15-minute phone consultation, or request an appointment, and we will start by figuring out what is actually going on.
Disclaimer
This content is for educational purposes only and is not medical advice, diagnosis, or treatment. Individual results vary and no outcome is guaranteed. Venturis Clinic offers regenerative, functional, and alternative medicine services; some therapies discussed are not FDA-approved for the uses described. Talk with a qualified healthcare provider about your specific situation before beginning any treatment.
Sources
- Pandolfi S, Ghezzi C, Bjorklund G, Metalla M, Paone FM, Chirumbolo S. NAD+ biology and supplementation: from mechanisms to clinical perspectives. Molecular Biology Reports. 2026;53(1):1249. DOI: 10.1007/s11033-026-12351-3
- Abanades S, Fernandez I, Capdevila N, Cardona F. Micronutrition as a Therapeutic Strategy for Mitochondrial Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia: A Narrative Review. Nutrients. 2026;18(16):2702. DOI: 10.3390/nu18162702
- Kurtz JA, Singleton KM, Vasenina E, et al. Targeted Supplementation and Nutritional Strategies for Healthy Aging: A Review of Physiological and Molecular Benefits. Current Nutrition Reports. 2026;15(1):53. DOI: 10.1007/s13668-026-00776-y
- Vinten KT, Tretowicz MM, Coskun E, et al. NAD+ precursor supplementation in human ageing: clinical evidence and challenges. Nature Metabolism. 2025;7(10):1974-1990. DOI: 10.1038/s42255-025-01387-7
